Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations

P450 oxidoreductase (POR) is an electron-donating flavoprotein required for the activity of all microsomal cytochrome P450 enzymes. We sequenced 5,655 bp of the POR gene in a representative population of 842 healthy unrelated individuals in four ethnic groups: 218 African Americans, 260 Caucasian Americans, 179 Chinese Americans, and 185 Mexican Americans. One hundred forty SNPs were detected, of which 43 were found in ≥1% of alleles. Twelve SNPs were in the POR promoter region. Fifteen of 32 exonic variations altered the POR amino acid sequence; 13 of these 15 are previously undescribed missense variations. We found eight indels, only one of which was in the coding region. A previously described variant, A503V, was found on 27.9% of all alleles with some ethnic predilection (19.1% in African Americans, 26.4% in Caucasian Americans, 36.7% Chinese Americans, and 31.0% in Mexican Americans). We built cDNA expression vectors for the 13 previously undescribed missense variants, expressed each protein lacking 27 N-terminal residues in Escherichia coli, and assayed the apparent Km and Vmax of each in four assays: reduction of cytochrome c, oxidation of NADPH, 17α-hydroxylase activity of P450c17, and 17,20 lyase activity of P450c17. The catalytic activities of several missense mutants differed substantially in these assays, indicating that each POR mutant must be assayed separately with each potential target P450 enzyme. The activity of A503V was reduced to a modest but statistically significant degree in all four assays, suggesting that it may play an important role in interindividual variation in drug response.

[1]  B. Masters.  The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. , 2005, Biochemical and biophysical research communications.

[2]  W. Miller,et al.  Minireview: regulation of steroidogenesis by electron transfer. , 2005, Endocrinology.

[3]  C. Kasper,et al.  Association of Multiple Developmental Defects and Embryonic Lethality with Loss of Microsomal NADPH-Cytochrome P450 Oxidoreductase* , 2002, The Journal of Biological Chemistry.

[4]  W. Miller,et al.  Cytochrome b 5 Augments the 17,20-Lyase Activity of Human P450c17 without Direct Electron Transfer* , 1998, The Journal of Biological Chemistry.

[5]  K. Jones,et al.  Missense mutation serine106----proline causes 17 alpha-hydroxylase deficiency. , 1991, The Journal of biological chemistry.

[6]  K. Tachibana,et al.  Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley–Bixler syndrome , 2004, American journal of medical genetics. Part A.

[7]  P. Ortiz de Montellano,et al.  Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. , 1998, Biochemistry.

[8]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[9]  L. Maltais,et al.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.

[10]  Joseph Sack,et al.  Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. , 2005, American journal of human genetics.

[11]  B. Masters,et al.  Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Ogata,et al.  Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  W. Miller,et al.  Protein Phosphatase 2A and Phosphoprotein SET Regulate Androgen Production by P450c17* , 2003, The Journal of Biological Chemistry.

[14]  N. Peet,et al.  Pharmacogenomics: challenges and opportunities. , 2001, Drug discovery today.

[15]  C. Wolf,et al.  Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.

[16]  F. Tajima.  Statistical analysis of DNA polymorphism. , 1993, Idengaku zasshi.

[17]  B. Masters,et al.  Diminished FAD Binding in the Y459H and V492E Antley-Bixler Syndrome Mutants of Human Cytochrome P450 Reductase* , 2006, Journal of Biological Chemistry.

[18]  M. Waterman,et al.  Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. , 1999, Biochemistry.

[19]  B. Henderson,et al.  A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans. , 2007, Cancer research.

[20]  E. Burchard,et al.  Functional Genetic Diversity in the High-Affinity Carnitine Transporter OCTN2 (SLC22A5) , 2006, Molecular Pharmacology.

[21]  F Peter Guengerich,et al.  Cytochrome P450: What Have We Learned and What Are the Future Issues? , 2004, Drug metabolism reviews.

[22]  Amit V Pandey,et al.  Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. , 2007, Molecular endocrinology.

[23]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .

[24]  E. Jabs,et al.  Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome , 2004, Nature Genetics.

[25]  M. Ingelman-Sundberg,et al.  Hormone controlled phosphorylation and degradation of CYP2B1 and CYP2E1 in isolated rat hepatocytes. , 1991, Biochemical and biophysical research communications.

[26]  D. Hartl,et al.  Principles of population genetics , 1981 .

[27]  M. J. Coon,et al.  Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components. , 1969, The Journal of biological chemistry.

[28]  N. Risch,et al.  Functional genomics of membrane transporters in human populations. , 2005, Genome research.

[29]  C. Shackleton,et al.  Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study , 2004, The Lancet.

[30]  A. Doherty,et al.  Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. , 2007, Molecular endocrinology.

[31]  Conrad C. Huang,et al.  Natural variation in human membrane transporter genes reveals evolutionary and functional constraints , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[33]  B. Horecker.  TRIPHOSPHOPYRIDINE NUCLEOTIDE-CYTOCHROME c REDUCTASE IN LIVER , 1950 .

[34]  C. Tickle,et al.  Identification of Novel Roles of the Cytochrome P450 System in Early Embryogenesis: Effects on Vasculogenesis and Retinoic Acid Homeostasis , 2003, Molecular and Cellular Biology.

[35]  W L Miller,et al.  Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  W. Miller,et al.  Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. , 2007, The Journal of clinical endocrinology and metabolism.

[37]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[38]  M. Cargill.  Characterization of single-nucleotide polymorphisms in coding regions of human genes , 1999, Nature Genetics.

[39]  R B Altman,et al.  The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response , 2007, Clinical pharmacology and therapeutics.